Emergent BioSolutions Inc.
EBS · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $1 | $1 | $1 | $1 |
| Enterprise Value | $1 | $1 | $1 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 64% | -36.6% | 14.1% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 60.3% | 43.1% | 53.7% | 70.1% |
| EBITDA | $0 | $0 | $0 | $0 |
| % Margin | 41.6% | 16.7% | 33.8% | 10.8% |
| Net Income | $0 | -$0 | $0 | -$0 |
| % Margin | 22.2% | -8.5% | 30.6% | -16.1% |
| EPS Diluted | 0.91 | -0.22 | 1.19 | -0.59 |
| % Growth | 513.6% | -118.5% | 301.7% | – |
| Operating Cash Flow | -$0 | $0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | $0 | -$0 | -$0 |